Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chorea

Chorea

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chorea

4 trials tracked for Chorea: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 396 citations.

4Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 3
  1. Phase 3 First Time Use of SD-809 in Huntington Disease Completed · 396 cited
  2. Phase 2 Atomoxetine and Huntington's Disease Completed
  3. Phase 2 Citalopram to Enhance Cognition in HD Completed
  4. Phase 2 Risperidone for the Treatment of Huntington's Disease Involuntary Movements Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease
Neurology FDA Approval
FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease FDA approves a new sprinkle version of Ingrezza for two movement disorders
The FDA has approved Ingrezza Sprinkle, a VMAT2 inhibitor, for the treatment of adults with tardive dyskinesia and chorea associated with Hu…
FDA approves sprinkle form of Ingrezza to treat involuntary movements in adults with tardive dyskinesia or Huntington's disease chorea.
FDA Apr 10, 2026